Active	Status	Sponsor type	Region	Phase	Filter
10 Active 10 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Harrison, Michael R
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension	Active, not recruiting	3	1083	Europe, Canada, US, RoW	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	12/24	02/25
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma	Recruiting	N/A	800	US		Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer	Metastatic Renal Cell Carcinoma	07/26	07/26
TRIO CAP, NCT05017935: RADIANCE Continued Access Protocol	Active, not recruiting	N/A	300	US	Renal Denervation	ReCor Medical, Inc.	Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases	12/28	12/28